LOXO ONCOLOGY, INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 2013-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.loxooncology.com
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03899792
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
๐บ๐ธCincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 860
- Registration Number
- NCT03740529
- Locations
- ๐บ๐ธ
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
๐บ๐ธOhio State University Hospital, Columbus, Ohio, United States
๐บ๐ธCleveland Clinic Foundation, Cleveland, Ohio, United States
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 856
- Registration Number
- NCT03157128
- Locations
- ๐ฏ๐ต
Okayama University Hospital, Okayama, Japan
๐บ๐ธMayo Clinic of Scottsdale, Scottsdale, Arizona, United States
๐บ๐ธCity of Hope National Medical Center, Duarte, California, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath